MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
36.2 M |
Market Cap[1] |
$ 14.1 M |
EBITDA (LTM) |
$ -7.19 M |
P/E (LTM) |
-2.26087 |
P/S (LTM) |
6.089176 |
EPS (LTM) |
-0.23 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
$ 21.33 | -2.11 % | $ 239 M | Nasdaq Global Select Market,SPB | USA |
 |
Adagene
ADAG
|
$ 2.02 | -4.95 % | $ 119 M | Nasdaq Global Market |  China |
 |
Benitec Biopharma
BNTC
|
$ 9.31 | -5.67 % | $ 433 M | Nasdaq Capital Market | USA |
 |
Denali Therapeutics
DNLI
|
$ 19.85 | -2.36 % | $ 3.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.75 | 0.09 % | $ 4.88 B | Nasdaq Global Market |  Irlanda |
 |
ImmuCell Corporation
ICCC
|
$ 10.4 | 1.76 % | $ 93.9 M | Nasdaq Global Select Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.5 | -9.09 % | $ 222 M | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.77 | 1.23 % | $ 1.84 B | Nasdaq Global Select Market,SPB | USA |
 |
Cue Biopharma
CUE
|
$ 18.89 | -6.21 % | $ 1.79 B | Nasdaq Capital Market,SPB | USA |
 |
Equillium
EQ
|
$ 1.45 | -3.33 % | $ 83.1 M | Nasdaq Global Market | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.6 | -14.05 % | $ 91 M | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 2.46 | -3.35 % | $ 130 M | Nasdaq Capital Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 18.13 | 9.85 % | $ 3.05 B | Nasdaq Global Select Market,SPB | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.21 | 3.76 % | $ 19 M | Nasdaq Capital Market | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.51 | -9.88 % | $ 192 M | NYSE |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 33.57 | -0.62 % | $ 1.93 B | Nasdaq Global Select Market | USA |
 |
Ardelyx
ARDX
|
$ 3.0 | 2.39 % | $ 723 M | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.54 | 1.8 % | $ 139 M | Nasdaq Global Market | USA |
 |
Alector
ALEC
|
$ 2.54 | 3.05 % | $ 262 M | Nasdaq Global Select Market,SPB | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.11 | -13.62 % | $ 59.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 21.39 | 0.52 % | $ 6.7 B | NYSE | USA |
 |
Phathom Pharmaceuticals
PHAT
|
$ 5.45 | 2.16 % | $ 397 M | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.8 | 2.15 % | $ 728 M | Nasdaq Global Select Market |  Canada |
 |
Agenus
AGEN
|
$ 7.02 | -1.82 % | $ 209 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 12.44 | -0.52 % | $ 3.72 B | Nasdaq Global Select Market | Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.14 | 2.01 % | $ 405 K | Nasdaq Global Select Market | USA |
|
Immatics N.V.
IMTX
|
$ 6.42 | -0.23 % | $ 785 M | Nasdaq Global Select Market |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.08 | -4.42 % | $ 341 K | Nasdaq Capital Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 2.59 | -34.43 % | $ 25.6 M | Nasdaq Global Select Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 4.13 | -2.5 % | $ 506 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.38 | -2.91 % | $ 4.46 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.24 | -3.15 % | $ 3.23 M | Nasdaq Capital Market | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.68 | 5.93 % | $ 223 M | Nasdaq Global Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | Germany |
 |
Pliant Therapeutics
PLRX
|
$ 0.78 | -2.19 % | $ 47.9 M | Nasdaq Global Select Market | USA |
 |
Pharming Group N.V.
PHAR
|
$ 13.02 | -1.06 % | $ 8.97 B | Nasdaq Global Select Market |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.91 | -9.54 % | $ 414 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 29.06 | -1.09 % | $ 1.36 B | Nasdaq Global Select Market | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market | China |
 |
Aquestive Therapeutics
AQST
|
$ 3.52 | -0.56 % | $ 376 M | Nasdaq Global Market | USA |
 |
Jaguar Health
JAGX
|
$ 0.44 | -0.21 % | $ 1.03 M | Nasdaq Capital Market | USA |
 |
Arvinas
ARVN
|
$ 6.9 | 2.07 % | $ 489 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 1.95 | -6.04 % | $ 372 M | Nasdaq Global Market | USA |
 |
Beam Therapeutics
BEAM
|
$ 25.16 | -6.88 % | $ 2.49 B | Nasdaq Global Select Market | USA |
 |
Pulmatrix
PULM
|
$ 1.39 | 2.58 % | $ 5.08 B | Nasdaq Global Select Market | USA |
 |
Fortress Biotech
FBIO
|
$ 1.9 | -4.52 % | $ 53 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 90.63 | -1.21 % | $ 4.27 B | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.